Use our free peptide cheat sheet to organize peptide and GLP-1 comparison notes before choosing a compounded route
By activating these receptors, tirzepatide: Enhances glucose-dependent insulin secretion from pancreatic beta cells, reducing blood glucose levels without causing hypoglycaemia when glucose levels are normal (though risk increases when used with insulin or sulfonylureas) Suppresses glucagon release from pancreatic alpha cells, further improving glycaemic control Slows gastric emptying , which moderates postprandial glucose excursions, though this effect may diminish over time due to tachyphylaxis Reduces appetite and food intake through central nervous system pathways, contributing to significant weight loss Tirzepatide is administered once weekly via subcutaneous injection, with doses typically titrated from 2
What youll learn: Stopping tirzepatide is a transition, as the appetite and digestion support it provides slowly fades
When combined with a healthy diet and regular exercise, clinical trials have shown that patients can lose at least 20% of their body weight in 18 months
They are caused by bacteria introduced during the injection process and require antibiotic treatment
Both medications contain semaglutide GLP-1, which is prescribed alongside personalized lifestyle guidance to support weight loss for individuals with obesity or overweight-related health concerns
